Biogen Halts ALS Asset Agreement with Karyopharm

Biogen has terminated its asset purchase agreement with Karyopharm Therapeutics, putting a halt to the development of KPT-350 (BIIB100), which was being tested in Phase 1 as a treatment for amyotrophic lateral sclerosis (ALS).